Lyell Immunopharma (LYEL) Cash & Equivalents: 2019-2025
Historic Cash & Equivalents for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to $123.6 million.
- Lyell Immunopharma's Cash & Equivalents rose 23.21% to $123.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.6 million, marking a year-over-year increase of 23.21%. This contributed to the annual value of $105.6 million for FY2024, which is 27.50% down from last year.
- Latest data reveals that Lyell Immunopharma reported Cash & Equivalents of $123.6 million as of Q3 2025, which was up 25.07% from $98.8 million recorded in Q2 2025.
- Lyell Immunopharma's 5-year Cash & Equivalents high stood at $564.4 million for Q2 2021, and its period low was $98.8 million during Q2 2025.
- Over the past 3 years, Lyell Immunopharma's median Cash & Equivalents value was $123.6 million (recorded in 2025), while the average stood at $143.0 million.
- Per our database at Business Quant, Lyell Immunopharma's Cash & Equivalents skyrocketed by 191.75% in 2021 and then slumped by 70.44% in 2022.
- Lyell Immunopharma's Cash & Equivalents (Quarterly) stood at $293.8 million in 2021, then plummeted by 57.95% to $123.6 million in 2022, then increased by 17.88% to $145.6 million in 2023, then declined by 27.50% to $105.6 million in 2024, then increased by 23.21% to $123.6 million in 2025.
- Its Cash & Equivalents stands at $123.6 million for Q3 2025, versus $98.8 million for Q2 2025 and $120.3 million for Q1 2025.